Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland
Frontiers in Psychiatry · 13.07.2026 · 17
DOI: 10.3389/fpsyt.2026.1835310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 13.07.2026. Verfasst von Krzysztof Tomasiewicz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Themen: Psychiatrische Pflege
Abstract (Originalsprache)
Background
Patients with mental disorders are at increased risk of hepatitis C virus (HCV) infection, yet the prevalence of HCV among patients in Polish psychiatric ward remains unknown.
Methods
A cross-sectional survey was conducted in Poland from 2021 to 2023 in psychiatric wards. Adults recently hospitalized with at least one current mental health condition were eligible and 12–897 individuals were tested for anti HCV antibodies. Patients with confirmed active HCV infection (subsequent nucleic acid testing) were offered treatment.
Results
Of the 12,897 individuals who constituted the sample, 64% were male, and the median age was 45 years (interquartile range: 35–58 years). Among those subjects, 226 patients (representing 1.8% of the total) exhibited a positive HCV antibody test result, and 172 of these patients had active HCV infection (the prevalence of 1.3%). Multivariate analysis identified five risk factors for HCV infection within the investigated population: intravenous drug use (odds ratio [OR] = 9.40; 95% confidence interval [CI]: 6.12–14.44; p<0.001), diagnosed and treated liver disease (OR = 6.17; 95% CI: 4.10–9.26; p < 0.001); blood transfusions prior to 1992 (OR = 2.61; 95% CI: 1.29–5.28; p=0.008), diagnosis of mental and behavioral disorders due to psychoactive substance abuse (OR = 1.97; 95% CI: 1.34–2.91; p=0.001) and previous incarceration (OR = 1.62; 95% CI: 1.08–2.43, p=0.018).
Conclusions
High prevalence of HCV infection in patients with mental health disorders and specifically in patients who used intravenous drugs suggests the importance of screening for HCV in this vulnerable population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland.
- Department of Adult Psychiatry, Medical University of Lodz, Lódź, Poland.
- Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland.
- Department of Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
- Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, Toruń, Poland.
- Department of Infectious Diseases and Hepatology, Medical University of Lodz, Lódź, Poland.
Förderung
- Gilead Sciences
Zitieren
APA
Tomasiewicz, K., Gałecki, P., Jaroszewicz, J., Opoka, J., Pawłowska, M., Piekarska, A., Simon, K., Zarębska-Michaluk, D., Władysiuk, M., Prycel, T., Ros, S., Obierzyński, D., Halota, W., & Flisiak, R. (2026). Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1835310
Vancouver
Tomasiewicz K, Gałecki P, Jaroszewicz J, Opoka J, Pawłowska M, Piekarska A, et al. Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1835310
BibTeX
@article{Tomasiewicz2026,
author = {Tomasiewicz, Krzysztof and Gałecki, Piotr and Jaroszewicz, Jerzy and Opoka, Jolanta and Pawłowska, Małgorzata and Piekarska, Anna and Simon, Krzysztof and Zarębska-Michaluk, Dorota and Władysiuk, Magdalena and Prycel, Tomasz and Ros, Sławomir and Obierzyński, Dominik and Halota, Waldemar and Flisiak, Robert},
title = {Prevalence and predictors of HCV infection among hospitalized psychiatric patients in Poland},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1835310}
}
EUVIMED